PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Myocardial Infarction Research

Background:

• Ischaemic heart disease is a leading cause of mortality worldwide.
• Improved survival post-myocardial infarction (MI) increases heart failure (HF) prevalence due to chronic cardiac remodeling.
• Current HF treatments for post-MI remodeling are limited.

Purpose of the Study:

• To investigate the role of plasma membrane calcium ATPase 4 (PMCA4) in cardiac remodeling and outcomes following MI.
• To determine if genetic or pharmacological loss of PMCA4 impacts post-MI cardiac function.
• To explore the effect of PMCA4 on fibroblast-mediated Wnt signaling in the infarcted heart.

Main Methods:

• Genetic deletion of PMCA4 (global, cardiomyocyte-specific, fibroblast-specific).
• Pharmacological inhibition of PMCA4.
• Assessment of chronic cardiac remodeling and functional outcomes post-MI.
• Evaluation of acute arrhythmic events in PMCA4-ablated hearts.

Main Results:

• Neither genetic deletion nor pharmacological inhibition of PMCA4 affected chronic remodeling of the post-MI myocardium.
• PMCA4 loss did not alter cardiac outcomes in the chronic phase after MI.
• PMCA4-ablated hearts exhibited reduced susceptibility to acute arrhythmic events post-MI.
• A potential slight survival benefit was observed in PMCA4-ablated hearts due to reduced arrhythmias.

Conclusions:

• PMCA4 inhibition does not impact chronic cardiac remodeling or outcomes following myocardial infarction.
• PMCA4 plays a role in acute arrhythmic events post-MI, potentially offering a therapeutic target for reducing sudden cardiac death.
• Further research is needed to fully elucidate the role of PMCA4 in cardiac pathophysiology.